The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.
Epistemonikos ID: fde0f5643c9c5797a5d49cbe0ab935d7c6b3e3a0
First added on: May 07, 2024